Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (391-400 of 713) with videos related to

Pageof 72
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemiaNaveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, et al.
Blood|May 20, 2006
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Blood|December 17, 2009
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisFabio P S Santos, Hagop M Kantarjian, Nitin Jain, et al.
Blood|September 24, 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemiasDan Jones, Rajyalakshmi Luthra, Jorge Cortes, et al.
Cancer|May 10, 2012
Clinical and proteomic characterization of acute myeloid leukemia with mutated RASTapan M Kadia, Hagop Kantarjian, Steven Kornblau, et al.
Cancer|July 14, 2011
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeStefan Faderl, Guillermo Garcia-Manero, Elias Jabbour, et al.
Plos One|November 14, 2013
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cellsSteven M Kornblau, Amina Qutub, Hui Yao, et al.
Journal of Clinical and Experimental Dentistry|April 14, 2022
Long term follow-up of a full- arch rehabilitation with an implant-supported overdenture on four zirconia implants and a zirconia bar. A case reportJesús Peláez, Judith Gelfo-Flores, Maria-Isabel Albanchez-González, et al.
Cancers|June 12, 2026
Higher Cumulative Cytarabine Consolidation Improves Survival in Older Adults with Acute Myeloid LeukemiaTodd William Mudd, Kendall Diebold, Sravanti Rangaraju, et al.
Pageof 72

Showing results (391-400 of 713) with videos related to

Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemiaNaveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, et al.
Blood|May 20, 2006
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Blood|December 17, 2009
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisFabio P S Santos, Hagop M Kantarjian, Nitin Jain, et al.
Blood|September 24, 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemiasDan Jones, Rajyalakshmi Luthra, Jorge Cortes, et al.
Cancer|May 10, 2012
Clinical and proteomic characterization of acute myeloid leukemia with mutated RASTapan M Kadia, Hagop Kantarjian, Steven Kornblau, et al.
Cancer|July 14, 2011
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeStefan Faderl, Guillermo Garcia-Manero, Elias Jabbour, et al.
Plos One|November 14, 2013
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cellsSteven M Kornblau, Amina Qutub, Hui Yao, et al.
Journal of Clinical and Experimental Dentistry|April 14, 2022
Long term follow-up of a full- arch rehabilitation with an implant-supported overdenture on four zirconia implants and a zirconia bar. A case reportJesús Peláez, Judith Gelfo-Flores, Maria-Isabel Albanchez-González, et al.
Cancers|June 12, 2026
Higher Cumulative Cytarabine Consolidation Improves Survival in Older Adults with Acute Myeloid LeukemiaTodd William Mudd, Kendall Diebold, Sravanti Rangaraju, et al.
Pageof 72